TLIS Stock Overview
Operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Talis Biomedical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.43 |
| 52 Week High | US$9.60 |
| 52 Week Low | US$4.35 |
| Beta | 1.69 |
| 11 Month Change | -8.37% |
| 3 Month Change | 5.38% |
| 1 Year Change | 17.16% |
| 33 Year Change | -94.48% |
| 5 Year Change | n/a |
| Change since IPO | -97.98% |
Recent News & Updates
Recent updates
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate
Aug 16
Talis Biomedical reports Q2 results
Aug 02Talis Biomedical Aims For Manufacturing Turnaround
Mar 17Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely
Feb 08Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Nov 04Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Jul 21News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat
May 18Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 14Shareholder Returns
| TLIS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.3% | -0.9% | 0.5% |
| 1Y | 17.2% | -2.6% | 20.5% |
Return vs Industry: TLIS exceeded the US Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: TLIS underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| TLIS volatility | |
|---|---|
| TLIS Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TLIS has not had significant price volatility in the past 3 months.
Volatility Over Time: TLIS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 99 | Rob Kelley | talisbio.com |
Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.
Talis Biomedical Corporation Fundamentals Summary
| TLIS fundamental statistics | |
|---|---|
| Market cap | US$15.78m |
| Earnings (TTM) | -US$57.21m |
| Revenue (TTM) | US$989.00k |
15.5x
P/S Ratio-0.3x
P/E RatioIs TLIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLIS income statement (TTM) | |
|---|---|
| Revenue | US$989.00k |
| Cost of Revenue | US$29.46m |
| Gross Profit | -US$28.47m |
| Other Expenses | US$28.74m |
| Earnings | -US$57.21m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -31.40 |
| Gross Margin | -2,878.56% |
| Net Profit Margin | -5,784.73% |
| Debt/Equity Ratio | 0% |
How did TLIS perform over the long term?
See historical performance and comparison